Women with stage IV triple-negative breast cancer tumors are much less likely to benefit from surgery than those with hormone-positive or Her2-positive disease. Researchers at Memorial Sloan-Kettering Cancer Center in New York evaluated 186 patients with stage IV tumors, 68 of whom had surgery. Those with ER+, PR+, or Her2+ saw improved survival rates with surgery. Those with triple negative, however, had no survival benefit. The study was published in the journal Cancer (January 2010.)
No comments:
Post a Comment